News stories about Allergan (NYSE:AGN) have been trending positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Allergan earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.3031879411709 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
Shares of Allergan (NYSE:AGN) traded down $3.65 during mid-day trading on Tuesday, hitting $158.72. The stock had a trading volume of 3,250,000 shares, compared to its average volume of 3,110,000. The stock has a market cap of $54,030.00, a P/E ratio of -13.24, a price-to-earnings-growth ratio of 1.17 and a beta of 1.19. Allergan has a fifty-two week low of $156.11 and a fifty-two week high of $256.80. The company has a current ratio of 2.04, a quick ratio of 1.88 and a debt-to-equity ratio of 0.41.
Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. The business had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The company’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.90 EPS. analysts expect that Allergan will post 15.56 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be issued a $0.72 dividend. The ex-dividend date is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.81%. This is a boost from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio is currently -23.35%.
Several research firms have commented on AGN. Royal Bank of Canada reaffirmed an “outperform” rating and set a $250.00 price objective (down from $277.00) on shares of Allergan in a research note on Thursday, October 19th. They noted that the move was a valuation call. JPMorgan Chase & Co. set a $275.00 price objective on Allergan and gave the company a “buy” rating in a research note on Sunday, October 22nd. Wells Fargo & Co set a $245.00 price objective on Allergan and gave the company a “buy” rating in a research note on Friday, January 5th. Credit Suisse Group set a $214.00 target price on Allergan and gave the stock a “buy” rating in a research note on Tuesday, December 19th. They noted that the move was a valuation call. Finally, Mizuho downgraded Allergan from a “buy” rating to a “neutral” rating and set a $193.00 target price for the company. in a research note on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $227.23.
In related news, insider William Meury sold 11,807 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christopher J. Coughlin purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was purchased at an average price of $163.30 per share, for a total transaction of $1,633,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Allergan (AGN) Earns Daily News Impact Score of 0.26” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/allergan-agn-earns-daily-news-impact-score-of-0-26.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.